STEPHANIE O'MALLEY: Open Payments
NPI 1366177420 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,196 in 149 payments from 23 companies in 2025. Trend: 2023 $3,901 · 2024 $3,646 · 2025 $3,196
Food & beverage: $3,124Education: $73
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $620 |
| Teva Pharmaceuticals USA, Inc. | 17 | $371 |
| E.R. Squibb & Sons, L.L.C. | 11 | $329 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $283 |
| Otsuka America Pharmaceutical, Inc. | 14 | $265 |
| Vanda Pharmaceuticals Inc. | 10 | $228 |
| Lundbeck LLC | 20 | $225 |
| Alkermes, Inc. | 11 | $197 |
| Axsome Therapeutics, Inc. | 5 | $120 |
| Bausch Health US, LLC | 4 | $90 |
Products named: INGREZZA, REXULTI, COBENFY, CAPLYTA, AUSTEDO XR, FANAPT, ARISTADA, REJOYN.
Industry payments across NY — which companies pay providers there.
